KIMS - IntraDay Trade Analysis with Live Signals

Last Updated Time : 20 Dec 25, 07:03 am

IntraDay Trade Rating: 2.8

📊 Analysis: KIMS is trading at ₹637, below both its 50 DMA (₹689) and 200 DMA (₹674), reflecting short-term weakness. RSI at 30.8 indicates oversold conditions, while MACD (-12.7) confirms bearish undertone. Intraday volume (3,85,441) is lower than the 1-week average (4,98,162), showing reduced participation. Despite modest PAT growth sequentially (₹58.8 Cr. → ₹63.7 Cr.), quarterly profit variation is negative (-11.8%), and valuation is stretched with a P/E of 89.8 vs industry 51.8. Intraday signals lean bearish, making it a cautious candidate.

💡 Optimal Buy Price: ₹628–632 if price stabilizes near support.

🎯 Profit-Taking Exit Levels: ₹648 (minor resistance), ₹660 (short-term recovery zone).

🛡️ Stop-Loss: ₹620 to protect against downside risk.

⏱️ If Already Holding: Exit intraday if price fails to hold above ₹628 or RSI dips below 30 with declining volume. A bounce above ₹648 can be used for profit booking.

Positive

• 📈 Sequential PAT growth (₹58.8 Cr. → ₹63.7 Cr.)
• 💰 EPS at ₹7.30 shows earnings strength
• 🏭 ROCE (16%) and ROE (14%) indicate operational efficiency
• 🔄 DII holdings increased (+0.47%)

Limitation

• ⚠️ Very high P/E (89.8) compared to industry average (51.8)
• 📉 RSI at 30.8 indicates oversold but weak momentum
• 📊 MACD (-12.7) confirms bearish trend
• 🔻 Price below both 50 DMA and 200 DMA
• 📉 Intraday volume below weekly average

Company Negative News

• 📉 Quarterly profit variation (-11.8%) despite sequential improvement
• ⚠️ PEG ratio (299) signals poor valuation-growth alignment
• 🔻 Decline in FII holdings (-0.51%)

Company Positive News

• 📈 Sequential PAT improvement
• 💡 Strong ROCE and ROE highlight efficiency
• 💰 Debt-to-equity at 0.46, moderate leverage

Industry

• 🏥 Healthcare sector supported by rising demand for medical services
• 📊 Industry PE at 51.8, lower than company valuation
• 🌍 Long-term demand outlook remains positive with healthcare expansion

Conclusion

⚖️ KIMS shows moderate fundamentals but weak intraday momentum and stretched valuations. Oversold RSI may trigger a short-term bounce, but caution is advised. Suitable only for disciplined intraday trades near support with strict stop-loss. Better positioned for long-term monitoring than aggressive intraday setups.

Would you like me to extend this into a peer benchmarking overlay comparing KIMS against Apollo Hospitals, Narayana Hrudayalaya, and Max Healthcare for intraday positioning?